Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 2/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8692420 | 0.87 | GPR17 (0.48) | GPR17FBP1GRIN1MEN1CYP1A2 | |
| SCHEMBL19330831 | 0.85 | GPR17 (0.43) | GPR17FBP1GRIN1MEN1CYP1A2 | |
| SCHEMBL19331208 | 0.81 | GPR17 (0.46) | GPR17FBP1MEN1KMT2AHPGD | |
| SCHEMBL27374215 | 0.81 | GPR17 (0.60) | GPR17FBP1GRIN1MEN1CYP1A2 | |
| SCHEMBL29813056 | 0.80 | ALOX15 (0.52) | GPR17FBP1CYP1A2CYP2C9HPGD | |
| SCHEMBL6220087 | 0.80 | ALOX15 (0.52) | GPR17FBP1CYP1A2CYP2C9HPGD | |
| SCHEMBL8752557 | 0.80 | GPR17 (0.58) | GPR17FBP1GRIN1MEN1CYP1A2 | |
| SCHEMBL7535729 | 0.80 | GPR17 (0.58) | GPR17GRIN1MEN1KMT2AGRIN2D | |
| SCHEMBL266498 | 0.80 | GPR17 (0.70) | GPR17FBP1GRIN1MEN1CYP1A2 | |
| SCHEMBL7951010 | 0.78 | MEN1 (0.64) | GPR17MEN1CYP1A2BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040909-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230040909-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4034103-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746088-A | Indole carboxamide compounds and their use for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021062319-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021062319-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-07-11 | — | — | US | disclosed |
| WO-2002022576-A2 | 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | MKI67, FLT4, IDO1 | GPR17 1299/4885FBP1 963/4885GRIN1 3808/4885 |
| US-20230040909-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | IDO1, IDO2, INMT | GPR17 636/4885FBP1 684/4885GRIN1 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.